St. Jude Confirms 5-Year Data from FAME Trial Further Confirms Sustained, Long Term Benefit of FFR-Guided PCI

St. Jude Medical, Inc. 

today announced that five year results from the landmark FAME trial (Fractional Flow Reserve vs. Angiography in Multivessel Evaluation) have confirmed the long term benefits of fractional flow reserve (FFR) in guiding percutaneous coronary intervention (PCI) over angiography alone. An analysis of the study's five year follow up data confirms that in patients with multi-vessel coronary artery disease, FFR-guided PCI can contribute to reductions in all-cause mortality, cardiac mortality and an overall use of health care resources. The data, which were presented at the ESC Congress 2015, build upon previously-published results from the St. Jude Medical sponsored FAME trial at 12-months and